Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Biochemical Link Found Between Seemingly Unrelated Diabetes and Eczema

Nature study details how loss of caspase 8 protein releases interleukin 1-a, which causes the overproduction of skin. Scientists at UC San Diego (UCSD) have uncovered what appears to be a crucial biochemical link between diabetes and eczema, previously thought

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Nature study details how loss of caspase 8 protein releases interleukin 1-a, which causes the overproduction of skin.

Scientists at UC San Diego (UCSD) have uncovered what appears to be a crucial biochemical link between diabetes and eczema, previously thought to be two completely unrelated diseases. The researchers report that caspase 8, a protein previously linked only to cell death, plays a critical role in the healing of wounds in laboratory mice. The protein is deficient in humans with eczema, but produced in excess amounts by diabetics.

But the team wondered how caspase 8, which resides in cells at the surface of the epidermis, could account for this condition when the stem cells responsible for the proliferation phase are deeper in skin tissue and the infection-fighting cells in the blood vessels responsible for the inflammation phase are even deeper.

“What we discovered was that the loss of caspase 8 in the epidermis releases interleukin 1-a, which can travel deeper into the tissue to recruit immune cells and cause the local reservoirs of stem cells in the skin to start proliferating. This is the first time anyone has demonstrated that caspase 8 triggers the release of this protein and how it does so.”

The discovery, which appears in the March 26 issue of the journal Nature may clarify why many diabetics lack a normal wound response and suffer serious complications from trivial cuts and scrapes, and also explain why those with eczema exhibit a chronic inflammation of the skin that compromises its protective function.

“Not only does the loss of caspase 8 stimulate inflammation, which brings in a rush of cells designed to stop microbes from infecting the wound,” said Colin Jamora, Ph.D., assistant professor of biology at UCSD, “But it also stimulates the production of stem cells that provide the materials to help close the wound. That’s important, because in the initial stages of a wound the protective barrier provided by the skin is broken and the internal body is exposed to microbes and environmental toxins.”

The group made the surprise discovery when examining a mutant mouse that had been genetically engineered with unusually thick skin for a separate study that knocked out the gene in the epidermis necessary for the production of caspase 8.

The researchers initially suspected that the reason for the unusually thick-skinned mutant mouse was that the lack of caspase 8 in the epidermis was somehow interfering with the death program of the skin cells, leading to an accumulation of skin cells that should have otherwise died. “But what was actually happening was not that the skin cells were living longer, but that the lack of caspase 8 was stimulating more skin cells to divide, which was unexpected,” says Dr. Jamora. “And when we looked further, we also found that there was inflammation going on in the skin of these mice. Those two things led us to suspect that the loss of caspase 8 can trigger a normal wound-healing response in the absence of any trauma to the skin.”

The team is now studying laboratory mouse models of human diabetes, which produce excess amounts of caspase 8, to determine if artificially damping their production of caspase 8 will restore their ability to heal wounds.

“We are also using the caspase-8 knockout mouse as a model system to study eczema in order to identify the players that contribute to this disorder,” says Dr. Jamora.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
02How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →